Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06264258 · ClinicalTrials.gov registry record · NA

Game-based Pediatric Diabetes Education

A NA study of Diabetes Mellitus, Type 1 and Behavior, Health, sponsored by Carnegie Mellon University.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT06264258: Recruiting NA study of Diabetes Mellitus, Type 1 and Behavior, Health, sponsored by Carnegie Mellon University.

NCT06264258 is a NA study of Diabetes Mellitus, Type 1 and Behavior, Health that is actively recruiting participants, run by Carnegie Mellon University. The registered enrollment target is 80 participants, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06264258, a NA study of Diabetes Mellitus, Type 1 and Behavior, Health, is actively recruiting participants, sponsored by Carnegie Mellon University.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to evaluate the impact of a mobile app video game called Digital Vaccine for Type 1 Diabetes (DVx-T1D)™, proposed as a low-risk, non-invasive, digital therapeutic candidate for behavior change in children 6 to 12 years of age with Type 1 Diabetes (T1D). The investigators hypothesize that adoption of DVx-T1D™ by T1D patients will positively influence healthy dietary and physical activity behaviors by providing nutrition and lifestyle education through a playful, Artificial Intelligence (AI)-based, cartoon-style medium of mobile gaming, and result in improvements in their T1D control. The investigators propose to conduct a longitudinal randomized controlled trial (RCT) over a 3-month period with a study population of 80 T1D participants (40 each in two arms of the trial) of 6-12 years old. The investigators will quantify the impact of the mobile game app plus standard care vs. standard care (with no exposure to the app) on T1D control (assessed by glycosylated hemoglobin or HbA1c measured during clinic visits and continuous glucose monitoring (CGM) parameters measured at home), physical activity levels and food choices of children (measured using food logs and surveys). Game telemetry, food logs, clinical, anthropometric, demographic, and survey data will be collected to obtain adequately powered, theory-driven evidence of the value of game-based approaches delivered via mobile apps.

Interventions

  • BEHAVIORAL DVx-T1D™ app

Study Locations (1)

Pennsylvania

  • UPMC Children's Hospital of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-05-22
Est. Completion 2026-06-30
Phase NA
Carnegie Mellon University

37 total trials

What NCT06264258 shows while recruiting

NCT06264258 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,265-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which DVx-T1D™ app is the first listed.

NCT06264258 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06264258 about?

NCT06264258 is a clinical study titled "Game-based Pediatric Diabetes Education". The goal of this study is to evaluate the impact of a mobile app video game called Digital Vaccine for Type 1 Diabetes (DVx-T1D)™, proposed as a low-risk, non-invasive, digital therapeutic candidate for behavior change in children 6 to 12 years of age with Type 1 Diabetes (T1D). The investigators h...

What is the current status of trial NCT06264258?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-05-22. Estimated completion is 2026-06-30.

What conditions does trial NCT06264258 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 1, Behavior, Health.

What interventions are being tested in trial NCT06264258?

The interventions under investigation include: DVx-T1D™ app (BEHAVIORAL).

Who is sponsoring clinical trial NCT06264258?

This trial is sponsored by Carnegie Mellon University, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06264258 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06264258's enrollment target sits among peer trials

80 53rd of 118 higher than 65 of 118 other Diabetes Mellitus, Type 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06264258, the US trial registry maintained by the National Library of Medicine. NCT06264258 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.